Search - tctmd.com

Displaying 81 - 100 of 132

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

News Daily News

Renal Denervation Shows Promise in Patients Refractory to Stenting

L.A. McKeown

May 02, 2014

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Yael L. Maxwell

March 29, 2014

News Daily News

Noninvasive Test Links Pre-Angiography Fluid Volume to Later Kidney Damage

Caitlin E. Cox

February 12, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

RE-LY: Dabigatran Safe, Effective Across Range of Renal Function

Yael L. Maxwell

December 30, 2013

News Daily News

RE-LY: Dabigatran es Seguro y Eficaz en Todos los Rangos de Función Renal

Yael L. Maxwell

December 30, 2013

News Daily News

RE-LY：达比加群在不同肾功能患者中安全、有效

Yael L. Maxwell

December 30, 2013

News Daily News

Bioengineered Vessels Appear Safe for Use in Dialysis Patients

November 21, 2013

News Conference News AHA 2013

Renal Stenting Fails to Improve Outcomes vs. Medical Therapy Alone in RAS Patients

Jason Kahn

November 17, 2013

News Conference News AHA 2013

Long-term Outcomes with Renal Denervation Show Sustained Benefit

Yael L. Maxwell

November 16, 2013

Presentation TCT 2013

Moving Away From Surrogate Measures: Rationale and Design for a Clinical Outcomes Trial of Renal Artery Denervation (EnligHTNment)

Presenter: Felix Mahfoud

October 27, 2013

Presentation TCT 2013

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Presenter: Andrew Farb

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Vessix (Boston Scientific)

Presenter: Ajay Kirtane

October 27, 2013

Presentation TCT 2013

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Presenter: David Kandzari

October 27, 2013

Advertisement

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Renal Denervation Shows Promise in Patients Refractory to Stenting

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure

Noninvasive Test Links Pre-Angiography Fluid Volume to Later Kidney Damage

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

RE-LY: Dabigatran Safe, Effective Across Range of Renal Function

RE-LY: Dabigatran es Seguro y Eficaz en Todos los Rangos de Función Renal

RE-LY：达比加群在不同肾功能患者中安全、有效

Bioengineered Vessels Appear Safe for Use in Dialysis Patients

Renal Stenting Fails to Improve Outcomes vs. Medical Therapy Alone in RAS Patients

Long-term Outcomes with Renal Denervation Show Sustained Benefit

Moving Away From Surrogate Measures: Rationale and Design for a Clinical Outcomes Trial of Renal Artery Denervation (EnligHTNment)

FDA Perspectives: Clinical Trial Regulatory Pathway for Renal Denervation Devices

Device and Clinical Trial Update: Vessix (Boston Scientific)

Device and Clinical Trial Update: Symplicity and Spyral (Medtronic)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content